<SEC-DOCUMENT>0001193125-12-410940.txt : 20121001
<SEC-HEADER>0001193125-12-410940.hdr.sgml : 20121001
<ACCEPTANCE-DATETIME>20121001135659
ACCESSION NUMBER:		0001193125-12-410940
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120928
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20121001
DATE AS OF CHANGE:		20121001

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AP PHARMA INC /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		121119452

	BUSINESS ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		6503662626

	MAIL ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		STREET 2:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d419480d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM&nbsp;8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act
of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>September&nbsp;28, 2012 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>A.P. PHARMA,
INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-33221</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94-2875566</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="31%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>123 Saginaw Drive</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Redwood City, CA</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94063</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code:&nbsp;(650)&nbsp;366-2626 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General
Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01&nbsp;Other Events. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;28, 2012, A.P. Pharma, Inc. (the &#147;Company&#148;) announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product
candidate, APF530, for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01&nbsp;Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit&nbsp;No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:72pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Document Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release issued on September&nbsp;28, 2012</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. PHARMA, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: October&nbsp;1, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John B. Whelan</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">John B. Whelan</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d419480dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px">


<IMG SRC="g419480img12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For Immediate Release </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma Resubmits New Drug Application for APF530, a Product Candidate for the Prevention of Chemotherapy-Induced Nausea and Vomiting </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">REDWOOD CITY, Calif. &#150; September&nbsp;28, 2012 &#150; A.P. Pharma, Inc. (OTCBB: APPA), a specialty pharmaceutical company, today announced that it has resubmitted its New Drug Application (NDA) to
the U.S. Food and Drug Administration (FDA) for its lead product candidate, APF530, for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). A.P. Pharma expects confirmation of acceptance from the FDA and a
Prescription Drug User Fee Act (PDUFA) goal date within the next few weeks. The Company anticipates a six-month review by FDA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;The
resubmission of the APF530 NDA is a pivotal milestone for A.P. Pharma and brings this important therapeutic option one step closer to cancer patients suffering from CINV,&#148; said John B. Whelan, A.P. Pharma&#146;s president and chief executive
officer. &#147;Now that we have resubmitted the NDA, our focus will shift to pre-marketing and pre-commercialization activities in anticipation of potential FDA approval of APF530.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About CINV </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prevention and control of nausea and vomiting, or emesis, are very important in
the treatment of cancer patients. The majority of patients receiving chemotherapy will experience some degree of emesis if not prevented with an antiemetic, typically administered just prior to chemotherapy. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chemotherapy treatments can be classified as moderately emetogenic, meaning that 30% to 90% of patients experience CINV, or highly emetogenic, meaning
that more than 90% of patients experience CINV, if they do not receive an antiemetic. Acute-onset CINV occurs within the first 24 hours following chemotherapy treatment. Delayed-onset CINV occurs more than 24 hours after treatment and may persist
for several days. Prevention of CINV is important because the distress caused by CINV can severely disrupt patient quality of life and can lead some patients to delay or discontinue chemotherapy. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About APF530 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma&#146;s lead
product, APF530, is in development for the prevention of both acute-onset and delayed-onset chemotherapy-induced nausea and vomiting (CINV). APF530 contains the 5-HT3 antagonist, granisetron, formulated in the Company&#146;s proprietary
Biochronomer&#153; drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. Intravenous and oral formulations containing granisetron are approved for the prevention of
acute-onset CINV, but not delayed-onset CINV. Granisetron was selected because it is widely prescribed by physicians based on a well-established record of safety and efficacy. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>- more -
</I></FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>A.P. Pharma Resubmits New Drug Application for APF530, </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>a Product Candidate for the Prevention of Chemotherapy-Induced Nausea and Vomiting</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page&nbsp;2</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About A.P. Pharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma is a specialty pharmaceutical company developing products using its proprietary Biochronomer&#153; polymer-based drug delivery platform. This drug delivery platform is designed to improve the
therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. The Company&#146;s lead product, APF530, is being
developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. For further information, please visit the Company&#146;s web site at www.appharma.com. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This news release contains &#147;forward-looking
statements&#148; as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including uncertainties associated with the potential approval of APF530 and the potential timing
for such approval, if approved at all, as well as risks relating to capital resources and liquidity, satisfactory completion of clinical studies, progress in research and development programs, launch and acceptance of new products and other risks
and uncertainties identified in the Company&#146;s filings with the Securities and Exchange Commission. We caution investors that forward-looking statements reflect our analysis only on their stated date. We do not intend to update them except as
required by law. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contacts </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investor Relations Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Rice
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office Phone: (646)&nbsp;597-6979 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Email: mrice@lifesciadvisors.com </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">and
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">John B.
Whelan, President and Chief Executive Officer </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office Phone: 650-366-2626 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>### </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g419480img12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g419480img12.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.P"Y`P$1``(1`0,1`?_$`+D```$#!0$!`0``````
M```````!"`D"`P8'"@4$"P$``00#`0$```````````````(&!P@!!`4#"1``
M``8!`P,"`P0'!0D!`````0(#!`4&!P`1""$2"3$305$B8105"G&!,D(C,Q:1
MH;$T&/!28H,D-387.#D1``$"!0,"!`4`!@<%"0````$"`P`1!`4&(1(',4%1
M82((<8$R$Q2AP4)2(Q7PD;%B<C,6\9(D-$31X8*R4R4U%QC_V@`,`P$``A$#
M$0`_`._C1!!H@@T01:54["CN&X].T/B8?D'Z-&G><O*,*!(TE/SZ1'=RD\H_
M#KB:=]#9`R,WLE^:IB)L:X[(2W6XBP@<2HRB;)4(JO[F*`"+YR@)0'?MU)F$
M\.9YFSH>M%"MN@5K]]T%+9$^LY3B),\YLX]P5E35TK6ZBO3I]AHA2Y^!D=/T
MQ!KEG\QSD9\[>M,&\=*C`1A5#)-IC*%CEK))F(!C;*G@JR$/&M3EV#<@O50W
M';<=63L_M(H5%(R*Z+<5IO0TA*0%=P%$J)`Z=!/K%6;Q[TKG)36.VEMME)(;
M4XI1.WHF8`3K*&IG\^O/T53'25P8B0RAC^T7%S\2)IB;<J0'&X^X?M#IW".^
MGN/:+Q&HI#AKPYW.\2G_`+D,1SW?<M+"G-E`E`.@+9G+YJAU6!OS%V2(V:C(
MODQABKV&KK+HI/;ABA>0@K&Q3W*55]_2<V^DXZ9(F`B)DD'3<X[;!N.P:8F9
M^T>UH86,0N*PYM.UMP`[CV3N$B/C(_"'UB'O+N?WT,Y;;VULJ4-SC9*2D=R!
M(CY&7QCJ$POFC&G(3&];RQB2TQ]OHUJ9_>8N68F.4Q%""*;V,DV:Q2.HR6C7
M)3).6JQ2*HJ%$#`&J<7VQ7+'KB[9KRTIBJ9,M>_74>(,M#W^,7HQW(K/E5G;
MO-E=0];'D3T,R"1.1UT.NHC;:8`!"@&^P`&V_KMKEZ_M?5'7:"4M@(GLEI.*
M]$>D&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"$W`/40T018%0I.I
MC[!N(?4(`'41`/AZ_+26VE(00I15J3,]O+Y1E"%.'<`1Y?KC4>:LZXKX]4&;
MRAE^ZQ-*I<$@!G,E).``[IRH.S:,BF20'>2TP]4V(BV0*=4XCT#;KKKXW8;K
ME-W;L./LN55P=.@`F!XDD#20U/E'`R;)[+AUG=O&2/(IJ)O69^H^``/69CCN
MYY^;3./(UU-8]P`ZE\)X3.=S'K/VJ_W;*5W9F,8@K3$PU-O5(MVGZ,F)P7[!
M`%5QZE"_G%?MOLN,!NZ9:A-9?$^HMN).QHG]T3U*>@4K^H1\Y^8/<U?LK4[9
M\56JCL*O3O;5)3H!_:.IUE.0E_;.#P5%#'74.JJHJY6,X<KJJJ*KN7!A[CKN
M5U3'6<+*&ZF.<QC&'U$=6DIFT4=,*.D2&Z4?LI$A%3*BH?JZ@U54M3E2?VE&
M9A"B382@`"(;&V`=P#;<-^T-]AZ:]D5;:9(`6D`2T&G]<H"T_O#H*2DB?7Q\
M8KW`=@*(B(B("&VVY@W`0Z@'4-A_LT.OJ6H(;WK)\>WZ(RI+CA*WBD-IZ"?C
MX:Q2/4AB#V]I@$.I1[?J'<1^D!'83=1$.ND[7VB-Z$R/CUA*$TV\*2I0<$=(
M7Y=3.=EB\NY?X\/GSE>HVRE_^TH2/44,9M%VNNR4?"SBC5(PB!!F8B32.L)0
M#O.V()MQW$:6^[S#Z/\`E-#E26T!W[A0I4M2")@&7@1/7Q/C%W_9OE59_/*O
M$U.+-(6]Z4$^D$3UEXRF.L==A%>FW<`&V$>W?TZ!T$?LU1I12%2D9?"/H.EU
MM1`*I$#6*@.81+N.PB`[%*("`[;;C^K?7FXXE,@`>L]1V$>@2E:_N-JFV!T^
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MN:`2-93API=0$^K=L$Y$]3K""8=@$3]OQZ]`$/U^H:\U!P*&A4)]OU]8/N)`
MF@Z'NKI\ND5=PB7?O+\P$NVVWQ^>AW[DOX2=?.,H7H?ND2\1_0Q0*P;``'V^
MW<-_I]=P^(:0-VX'U;.YGT/ATCS6ZWL"4K_B]O,?[(J*H!M_K#Z1^!BCT#YA
M^[TZZ6W]W7<GT]B>_P#3M'JEQHB:5;C+7R@$X=!]T``O4W4H^OH`A\!'?IH*
M'5I&X%"@KMW&ND$R!Z3-/6?ZH0#_`"4]/7J&_4=@$2[;Z4K<E6J9-^,8FEX[
MFE2\H4#B)>I_D41Z!]6VX^OQTA?WRK^$$E'ZH5N"@I7J2GMXPA#B(CW'Z[]H
M%[@#IUVZ"&_<.EE"P-@Z?O0E):<7O;4KI*1\1%TI@$P`!P'H/3X]!]?[M"6R
MA.NX^9A1/KD2/A%S1"HI,7<=]]OU:((T)R+Y!XUXPXCMN9LLS)(:I5)J"ITT
MQ(I*S<JL84XBNP#,YBC(3DV[[4FZ11]1$YA*0IC!VL:QFYY7=F,=LX*J]]T#
MH2`"K52I=$@&9,-K),MMV'66IR.^K2U;V6U$`J`*U`&24S[JEI')M-P.7O+J
M_NG*?D7R*QOQ?XE8QL;FO52$L$\SF5:;W`DF5FTJI)!@1>UR;=8/>E7Q@4<J
M;ILTC)$Z7@H;E9/;\MK#;!::FZY]4!*E.-ID%';V5M5()G+:"9==(H14T=Z]
MPSM1F62W>GM&"TJU(0AU05Z=TQ-.Y),Y3G+XSC`N1/B7Q]6.*]IY><6N541R
M,QS1A.XM:1X!K&*G9L)!O%S*L-(1<@N3\1A%'B9U6;E$@F2W,!@V#=QXES_?
M[KF[.#9S9GJ&_5!(02N6WT*7ZDE$S,).H/A#>S7V_6.U\?U&>X7>&*^RTZ05
MR1*<UI1-)"I?4H=IRB$KMZ%'?H8O=Z?,1V#U]>T`$?EOMJRZ%[V_N2E%35^E
M>SSB5SQP^,L>>53S1=9;*"V+(3%BL9%1KM.#8R+.<G7D0_EW))9^^>-DXN.C
MF2*'NKE*8Q$UA-ZAU@3F#G&KXVJ:6U4="*VKJ4D[0O[92`4@"6U6Y2MVG018
MGAG@M'*-MJ[H]7BBI*7ZE*;*T]3WW(E*1/6'?X6\-7&/.D)9Z?C3R`U/(7("
MIQBB]BKU&B8>5I4(_*842$7;+R`S\K!E?_P3/T#F#N-W``="C%=Z]Q/(&+5#
M5QN]B>I[&I822XO:HSUZ[=HZ=")Q*]F]MN!Y-3NVVPY%3U-\:23M0T="-/\`
MU)]>XT$0,9'HMCQ9?[MC6YMBLK70+/-5*PM2']Q,DK`O%&;L4%!*45$%13`Z
M9M@$Q#!T#5N;)?*7);129"S-0>92X`#^\`9'^N*?W^RU&+7RJQYXC<TX4*)!
M$I$CI/2<HG7_`"[F/9.;Y29;R,"*@0E$PZI`+._;'VAE;S8H\637WN@)K?A]
M><+"7<1[0#[-5;]W5X#>+6_''CMJ'7BH&?8)Z2Z]QWBV'LUMBWLRN%_;3_PK
M-)KX!2C],_D8>PQ\U_(?(.>LR83P-P_;9J?U*;N$'CU2J2\XJ]>%K-@4AT++
M>!42",AX19)LH<>PZ8JJB0A#]1'46CV_8G08I29)E5[_``'JBG0X6UMI,U*!
MFVE14F1&FLC\(E]_W)9=<,CK<8PVQBO_`!ZA;270L_2G0+*0DSGX3'Q[1G7#
MWR_YNNG+&,XC<P\$1&(+S:'[B"A'<.2;C'4#9U(]22B(6Q1,VX?D=L;`V1,#
M5XV6!,5#$#8>[IS<TX(LEIP'_7F(W(5]();T!,QM[G>"9;1J=.D;?'?N!R*Z
MYPK`LYMXH;@[HVJ>TI5KU21J"9`:@C7K&K/S'F4%&>.>.N%VCE05[9=;+D*3
M:I%.H"D?5HA&OPX*)I#[BH_BEA/V%#J=0H;=0UV/:=:`NZW7)'5(VTC("%*'
MI`4%%8G,:2&OEX1PO>5=UFTVG%*>?WZE[<4@ZK]0"?3\0?&-6VCR6<[N(^`\
M+/*?PI88PXTU2O4K&U:LF8V\N:RVQ>,KY2E7D&45+19ZF:RF8N%VX':+=H#]
M1SFWUW*'ASC?-,HN%"Y?C6994*<=VLIVMH!)(002LJV="=PTEH(X5RYOY,P3
M#[=4L6%-'C332&0IU6Y:E#0K!"4`;I@@2T\3'0=B;DRVR=Q%I_*5A1[*\2LN
M)R9(''U922F+.X=I1RSA[6X%%0S8DB^,^;'2;B82>X&PCUW#57;]AC]JR]S"
MJAU"5-5(:+JE;4)"I%*E$]``H3UT\8MQ8LW;N^`,9NMA9^]2ET-(!4I2DS!2
M/B4F6AT/2(3[AY)/*S9<;67DEC+AQ2L?<=ZRP?S_`'9+)(O[D\JT4J<LA+KQ
MZL_6Y%1LW*7=4[5EV`)3=AE`#NU/ENXJX2MMT8Q.\7Y=3D-2E`;_`!AZ`ZLC
MT*(WB8!Z%0,Y=)RBMUQY<YY7;ZC+[58D4V*4ZE%0J)[]B/VQ/89'43`(B5GQ
MW<TE^:O&)'-UDJS&CS\-/6*J7"+C'3AS`A*5INW>N)2'</-G248\CW::OMJB
M)T#=Q1,;8!&)N5./W>.\R5B](X:EM6PMJEZBE<I`CQUE/OX1-/%'*'_V/@RL
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MN.G3:1WA_<L<W9EQ]16*FHF:9[(:]K>ZSL(,YR*1ZC+73I#9>2OE`\J^$XRD
MYMMG&_'V$<*W.:;QE2K=NCOQ^PS9Q9'E2-;2L6?:SL"\DHYJJHF!6B`)@`]-
MP#=XX=P=P_F-75XQ;KI45N14VOW$'8WL!VDA,E`R)`T4?TPQ<XYZYRQ9FARB
MYVMBAQM_;-"P5*42)RW33*8U$Q&89U\G_DJGL'K<FL)\887"W'.%CH-T^OF2
MTV5EL4_^)*,F;V7B8!S*QIS50\HY]MJLFU6.HD(*";UUJ8YPEQ)09@K`LANK
MU9D2JE;24->A*9;CZE>L3`&H)!/81OY9SAS)68TC.L9M;-'BZ6DJ4XYZBHD#
MH/3I/OJ!$MWC@Y4WKESQ`J&=KY78]A=7+FWP,Q&UA`6K"=E*C)+L"R$(A(+@
M#(9WL#M2.L**:V^Q@+Z0?RSA5!@N:N8Q1/%VE0A"]YTV[NJ3UGM\8L'PWGUQ
MY"P)K*KLR!7%Q:-B=-VP`@C_`!=A^F(X;3RG\SN<AR+>\"<=Z+Q^QACI_9FB
M$1F!JQ6R!9$ZO[Q7XHFFW964@L0&YA%1J@@R,;Z4EU=NX95M&'>W.R-T=OR2
M[5=PO]4E*E"F!0VWOEM!T<U!^K6?D(B&\YQ[B[T[65^-VBGMU@IE+'\<[EJ^
MW]2AJB8(U2`.QUAW_B&YT9/YRX:O]BRY#5QA<<:W9K3W,M5VJ\:PLC5_"-IE
MN_<1"R[I..?-S*G2."2@I&``$`#KIC\V\=6;CK)J>BL;KJ[?4T_W4!9F0)RZ
MR$](?G`?*-ZY.Q^KJKZTRW7T=0&U%'[1(5K+L/3$M^H;B>8LG5*3J)RE*`;B
M81````'81$1Z``:#IKXD#YGH/G""XV`5$C:`23/H!U/P'C'"MY?>;\YR]Y(N
M,68_?.Y/#6'+(XI=*AF!U%$KO?\`[X$/-W$B93`616<21ACXL=A!-!,5"_SQ
MU](N`<#MW'N)'*[TU_[R^V7*@N"1:9E-*4S[RD?B3'RX]PG)%RY-S8XE:'"J
MSL/!JF2V24NNSVJ4J7:>[Y2\(VW+<!.'_!/&E'M?D8R3DFQY$R,R3LL'QJPL
MM]R31^XHB!5;'-**)G=+PY'8MW#LRK-N583)(B?KOQ6>4N2N2KT]0<1T%,U9
M:9\I_.?1N4")G_,F$B8U`(G*4.1/%7'/%UB8J^7*VI?O=6R%IHJ=8"9$@24`
M%'0@>4YSA^?+&T8:PWX2$UN/F-)/#E&Y+OZNC`TJP32TY8>V\SZ<S*2<M*+O
M'AG#J4K=:]XPD4,":9P+Z==0]@3&77WW$%[*:H5UVMSCGW%I`EZ$*;EZ=)`K
MT/A.)8Y&>QJP^W(M8Q2KH;5<DHV-NF2R"X')R($R=LY2Z=HY-E(J4:MBNW,;
M*(,SB0$WKB-?(,U05$?:.1VJW(V.*X[]O:8>[;IJ_P#25]"ZHV]IYI5<$S+8
M4"L#QV]91\[*FU71IC^8NT[R:`F0<*"$$^`5*7:.F7"8J<9/`-E>_%/^'V7D
M/)61O'+%,9NY62O5A9X\B`25**:I^VN1"RQ>T?V3"(=-4DRA@9Q[H**WH6E=
MNHT(0L3FA!0B:B>P._:D^9`B]6.*5@/M8JKHU_!K[@OZB)$A1F)=)^D*EY0W
M7\OGBZ=E^5=\R^9-2+H6)L13\/-S2_\``C/Q:VNV(,(A=T8"("9O&1;A\H43
M?PBI@(@&X#I[>[6]4CF&4F)A"/YK55#:D@?7Z`9Z#74J`^,-#V?6:I5F%9EC
MJUB@I:17W5&802N1!GTT"3.(O^74_-9KY.<B<V5BL6%]1[AEVZS,188^ORSB
M#5ADYW\.CG2<HDS-'F^]D:@(;J?690`]1#4T\;(MV)8=:;/=:IAJZ"E05-.+
M2EQ,D#JDF<AKVB"^1!7Y?F-SR*W4SSMI>K5I#J$*4WJM7[8$I].\=8_!O!3C
MQU^,[).1K>W_``K*,[CBX9NO9'!`3<Q4H%5<A1ZFL<P%$JL$R^[)J%'J#M97
MIOJA_)N6KY:Y<I*-I870L526VP"2E0"_4H>1E(R'1([&/H%QKBB.'^%*^]5#
M:D75^F74K2H;5H)0=J"#J""3U\8;7^7.QP9+$?(?-TR7>5OV1(FIMGJAMW!D
M*M$&G)?O5/N<I5YFQB)NO7LW'TZ/'W77K[M^MV-L^FGIF/N)2.ZE$)"0/+:=
M/,0S_9W:VFL>NF4O[5U#E44%1D?0/5N)\#NZ]-(;](.6/+OS\0DOC4Z4U4<*
M3<"XL5EC!(NP%KARMJ-IB1._1`Z"[=:XODV!#]W:J?M[1$0TZFB_Q_[:JA-X
M245EQW_;:<FE8#T@2E!]1VI.XR$-"K:9Y$]TJ*ZQ*2Y;Z%+8<<:]2)H4HS)'
MIF9:=STCW><I_P#4]YP>.6#0)^(5[%*^-&,NV*`J()H1RKS+EK]],0,F/>U(
MU24W#;M``'TUS^-@,-]M5WN[B5(J*E;J4*U!6'4);3M\9$RTZ0ODU:\V]S=G
MLB)KI;<IDJ2=0"VLN**O!,M3Y1N'\QCD%0V.N.&"89?W)&_9"G+FX9)CW"JA
M`1*=9A">V3<XIGE;,<"]-N\@`'77)]I5$AJ]W?**D?PJ:B7):M-A*%$B9Z'0
M0[O=_<&UVBRXJP/^*J*M)^VG]I.X`':.HG.',<O^9Z7B[XM\:L'XWIC"Z9NL
M-!K-+HE>DA43@HLL!#Q,3*V:>;-5&[U\4\\^!!LU(HF+ARK]1P*!M,S"..AS
M#EUVO=Z?<1CM*^ZZ^L?4I(*CM"CT](&LC(2D(>>?<FGAW";/CUDIT.Y!54[3
M=.@B:4J4!,[1J3N)T$M8C-\@-&\C%(XFR69.7O,Y)@K>W]=K#/C!C=@SAH21
M1LYR_BL).N8PL,1TSA8M,YW*:23U,IB`!U1]1F/BBZ<8W#.V,?P_'ONHHE+4
M*]V;CDT).U:E;=`3T491!/+]NY8MG'=1?\XOX1^<EM*+>B2$C<I).U,SN(3U
M3U$X?#Q8.;B5X+;5D10ZC"?M>+,EY"3.<H-U23.3'SJOU0"!])Q,1BZ8BG^\
M/3;X:C#)EUV<^X=NC;6AQ]-<V!K-(2R0L_(!)!\XE+!_P>//;0]<GD*2'J1P
MGLI2GIH$_CNT\HM?EZ,(Q57XLW+-,C#QXVK)F1IF'8V-5LD:8_H^GMV<4BP0
M?JD,X3CW,\+M4R9#`4Z@`)MQ`-M[W69,Y5YLS9$NE%-0L(#B4G^&I2AUETTT
MU/2>D)]H^,_@X>_D;C#*ZFNJ26U$`K2E,P1/_9,0USED9+E'YW\%8F2$LI7<
M.NL?-I-KL)FS<M18/<IV<%-NX@;O#MT3[_$I0'KIW8@PK$?;=<+XA9357)9*
M1^\-^P$>(V@`R[Q'^>J7FONAH++O0:*AV`Z@A)#84L$>.\F,@_,%V][?\I\1
MN+,&8SAY8Y1S9G3%$PB*LA<IV/H=9%0H;_40!="7<.GPUH>V!BCLMFO^55AV
M.?86V%DRVI,ES!_Q;1/QD(Z_NOK*Z[Y!8<+H%!>YQ"_MC7<H&7TC^Z2?A,PY
M#SGVUEA#QZ8[PA!]K,+=:<=T!%!J((@:L8XAPEY%),O[R(.(EF0P;;=JG735
M]M5O5D7+#]_N*E++277UK4=4J4L#=/S"E?UP[/=!4JQSBBEQ>WR:;>J&F@E(
MDE20VK<`/#=M^<H^B4Y,H>*CQ1<9!BZZSG\LW>G13>GP$D55&)+:[;'/+Y8K
M!82-S)KGCH!K*_6D0Z:CA44D@,4!$0]6L+1S+SG=*13Y1C[%0[N7,3+*%[0E
M).DS(RZZ3E"W<S'!7!5I<V)5D-53M[$'H'EH!)(ZZ3`/AWZ0S'D1CGFY(\,K
M1R]Y?\^;/2G-MH+2Q8\XXXR=LJM%SZMP0;?T]57XQSZ(2?%>MY0IW+9J@\.F
MV`P*+'$IAT\\/NW'K7(%+AV#8X*E#53]MVJJD;EI4C1:TF0(2%`!),A/QB/L
MVMO(E9QP_FN=Y'^(^XS]QFC86$I4A6J)B9F5"<P)](?G^7NQBM3^%TY?72*B
M2^7,L6F;;"8?H4AJLBRJ,<='_@.YCW/7[/73']U5XI[CR8BBH=IIJ.D#:I&<
ME[B9#Y=HE'VF6%5JXX5<GD2?KG]Y5W4$C0G_`'C$\>JV1:.&,>1W/#SC=PNS
MSE.'<%;V)A3E:W5%]]CHVBZO&U5AW26P"(JQ[B7^\%^U+4@<2XY_J_D:V61X
M3H%/)<7I.:6CO4)>81+YQ%G,.5#"N.+G>6I?EADM(_Q.^@?^:<?GP8\NCO'>
M0:)D-)HVFY"BW6KW-./DE#BVF7E:G&,R#-\M]2@$D%6?:=3ZA#NWZZ^KU\L:
M;MC-=8F?X1>8+23TT`V@CY"/D5C]Y-FRFDR%[^*&Z@.J'F5%1_MCH!Y5>4OQ
MT<H%:-DW(_#;(^4<QT2!7C*_`7&V1]9HK/[VY)(*1\^[A)QV>QPS:6W.GWQP
M'5*(EV*!M@J!AW!/+>*MU5NMEZ:H+&^]O40`I:C+:"$F6WTZ:*5K%P,YYZXA
MR_\`&NM^LC]?=J9L(1):DH`GN*20DS&Z9[&1AK/DA\F%#YK85P?A[&V*[!B>
M(QI-!*V.(<'@0K"WL5E.OQL34&D2N(-H^*.Y=%;IKD3$$A)N!1`=2!Q!PC=L
M`R"ZY!7UJ:UVL94E*Y'<E15]1)49GH#YS,1YS'S;C?(N/6BRVRA=HFZ%U*MF
MZ:)!,I2VITET^4?/SF\D6..3O%["?&+$&(K/CUICA_3QDY.P.:^Y/8D*E4U*
MU`,&0PVSH'#J3="NI[G0XE]-QUT>,N',IP/,;IG>3W`5%$[3NJ2F>@W*"NZC
M(2$OZ2CRY+Y<Q?.<&M>%8Q;C3US+[:5JE]4D[21Z1U)F=3*<3/<O\Z88X&<.
M^%7&O->"XC/V-[K18Z$R!0WS]-E)-$*;6H.7<V2$4=E*V-*-;?+`8H'.@80$
MW8H4W757L#Q/(^4<\ON2XW6FWU#-0XMMPCJ%.&0(F)@I`/732+,\@YCCO%_'
M6.XODMO%?9JBD:0^UNDI*@T-RDR!U"RK241*YV\L.-8;`=AXT\`N.QN,./;N
MF]3NEMD'S`;G+LY=`&\PG&-(U:33:OY=INV7D7;YRX*W$02!/UU8'%^`KB_D
M+&9<E79-UN5*D!AD2*!,[E*7J0=I2DCTIUU),A%>\NY\L=#C+V#\46O^6VM\
M_P`9\DJ<6!H$C0$"1(.JB>@D)SF]\0B<9F[@'CW&-JP/.U?%5-)$-XRQVV2C
M5&6:;%$V@]LE;)%P#)NF]+4VMD2(4BCE4Q7?M>V`&(7N-6;FUAW'N3ZNOM]U
M_*JG-TDH,PPD@C9,$ZZG02E.<O&UO`=-0Y5QC3VZYVD4]M1*:E"1>6/VQ,`Z
MZ:ZZQG/G%R@&-?'[D2(2>%;R.5+%3\;,P^H%%F<G+$F9XA``>X2C$PJH''?8
M"GV]->?MWQX9'R?1-.)]-.%/*/8;=H_JU,;ON9R!-BXHJT-*D_6*2RE/B"#H
M/AI$6/$WQ8\QY+C'BR^<>N:,WA"N9]I3:U9+QH]96-JR:GFE'0,W<.XKSLZB
MRSJO^R"X&!FN83#_`!NW8`FK.>:,";SBX4.38\U=5VRK4U3O!24F2"-3.9GN
M\(@SCK@/.:S`Z.Y8QD3EJI[E2I<?;*9@[@?-,A+L?@8FP\>_CAQ1P(J<V2$E
MGF0,K75)%*]9-F&!8YQ(M$5C.D("#C/?=_@U=;.E#*>V*RJSA<155.8P[!6_
MDWE"]<C/H34,AJRL%7V6$F>W=H221,F0`[#RGK%D^*N*K+Q92.!E[\F^5(2'
MJ@B6XIF1*1,M23UU^4:BPQXR[!0/(CDKG?=<LP]R-;W%U<UVDM:B^C'E;5M#
M-C!QHN9Q>9>-W_X)6V8M@[6Z8',?N#M#IKLW?E=JNXII>.J6B6T6G4*4YN!G
M)22?3*?;O'$Q_AJKLG*]9R775R*A%2VL)3MU25)4/&4A/XQ>YG^,F;YA<JL%
MYWF<O15<H.&25=$V-U:6YE7<\C$7'^KID"V,LZS18C.*HH(]6RH)D2W$#;[`
MC"N7V\$PZX8W24V^HKRH*=GTW)"92EV`\H5R+PQ59_G%LR^IN*44EOV%+6V?
MTDJZS[D]XM^33Q>K<])C%]\J>6@Q9?L8LW\*V<2%?=3\-+1+V01EVYP&-DHR
M3BI:(E$05;K)&.00.8#$WV,&QQ%R^QQBJJI;I0*N-IK`=Z$JVJ]0E(F1!$O&
M4>7,G##_`"DJBKK5<$T%UH2G8M2=R?29S'J$H9_D_P`%>5,\UJ&=YPY[Y(R3
MDV.<%;MYRS5!U+U&#KPL3MEHFNP#FTH.6C]PL!3J/3*@)R!V"GU[M/JU^Y"R
MXK<G1CN.,4MHJ`L(2A4G`M8(*EJ`E*730?&&!>?:Y>,HIV7LER1ZLN;>P'<D
M%HH000$C=,'24_#M$E7)'@BMF_A%5^&%6R:3'$9`PV,:\]MR-8":&1A<>D8F
M5:IPAYA@1N,NZCTU1$RZ@)[;"!O740XEGK.+<AG/7J0ONEQY01N(VEW=*:I'
MZ=WAK$T9AQU_J?CI/'C%4EE*4,H*ML]R6RDD2GWVQOCA_P`;HSB;QTQE@.,G
MC6I.@1+MH[LBD>6*4L$E(2KV7DI4\>5R\!H=TY>F^CW5````-]<+/,H>SG)J
MO(ZM&PU!3Z)S"0D``3EKTF?,PY>/\0I,"Q>FQBF5O#&X[NDRHD_KAG6$?&.A
MBWG;D[G%9,RO+W8;\K>3Q=+5I[>'85<+@I'MFYDID9J16>GAH1C]T(`HI`<#
MB;8/33XR+F!V_<>T?&]+2_CTE"E/K"I[Y341*0ZJ,SJ?.([QCA5C'>3:WDFL
MK`\[4*44ME.J2KQ43U\)"%S?XPVN=N=F-N9%HS*]3C<9J44T-B9.GMW+!1*C
M*.I%NDI8U)I-5,)">=F=*?\`2F[0*!0WZCKSQOEYW&>.ZS`::B"GZY"DJ?)D
M1N,SH!KT$C/20A&4\+C+N2:/D"NKI,42AM9"==!TW3TG+72/?\B7C=0\@;_#
MQI;,<ICB!Q6\GGJL''5-I/A8'4^I%$<K*.W4O'&CCHL8P42=I%-_=$P^FVL\
M7\MU7%S->BFI&ZBIKF@C>21M`!Z:'N9]8V>6.(*;E==$MRK73LT;F[9*>[4=
MNW2/?YZ>.:C\X\.8\Q@YNLIC66Q-((OJ+9HV(:SK9JC^"I0+J*E81TZ9D?L7
ML>V2`3%6343$FY1ZCK2XRY7NO&.2NWJE814_D((6E<]9DF8\YDS\9QO\F<1V
M?D_&6,?K75,.T9'VUI'0@;?U3T[PP!SX!(6X4-E6\L\R<W9!LU;;1L9C^6D&
M35Q5L=0C-4OWB.@*=,3,H4Y7;,@(%,9V0B!`Z)FV#4CL^Y2Y6N]JO%GLU`R'
M5J6H^K<I:I3)(E_8=(B+_P#*%JN-M%NO][KGW&TI2D`C:$)^D`&?GW$3,<3N
M/$-Q4P!C7`<#/NK1&XZAG$6G87S%O&O)I9U(O9-U(.6#55=NU67<OC"8I#B&
MH&R[(7LLR6IR*K3]NJJ5E92#-(T`TF!X193"\7H<,QRFQRVJ*Z2G3(*/4_&4
M.-TWX=,0S>=NO2\YX];RO%IK*(US(.+;#->SW_P85O:$F+MRL!-P%!%602,?
MN^D-MQVU.7MNJ&*7EJC+Z@EC[3J$SZ;E((T\R"?TQ7CW.43E5P_6K0C>XEUM
M:AXA"P=9=A(1POB81,/4HB'RVVV+L("4!Z[!N`AKZDNN*=("SN2.GP'3I'R9
M0I2`2C0'K\X4IS%-W%V`PB`B.Q=Q$.OR^8_KUC[B]GVY^@]H0I(4)*Z12``)
M@'M#?<=A#Z?4``>I>T?AI+;*5K2$I!4)R'0=/E"TK*$[9D([]_[9QZ,-,.*Y
M/0=@9MF;EW!2\7-M6T@W*ZCEW,-(MI%JD^:&53*[:*+MB@JGT[B".XZT[A2?
MS2V5%O6HMH<04*"3U2>H[_HCLV^Y?B5S-P9`5]A84-W[P[]M8=+RQYIYWYL6
M>DV3-;ROR4G2X9W5JO&5*M#!LDF\L]0?KH`P;N7BSJ4=*I(D`Q?VB)E*`;]!
MCO!.,<<XSIZBILQ5^(\-SRGE'T^*0HRT';KTZP^N0>2,LY6K:9NZ("JAA(0R
MEI.I3T!*1,$GO(#R`B6OQJ^%"YY7?5_-?+Z!E:7BQJ=K+5K$#Y-6,MN0";_>
M62]L32.5_6ZHH`%.+4Q@>/2"!3`B01[H)YA]R-LM5"YCV!.?=N7J0X^-0T.D
MF])**OF!+4]C8GA7VR5USJ&K]G-*EFW#:I#2B9N3U)4-TQ+X#J93CK[@8&%K
M,)%P5>B&$'#PL<TBXB(C&J3)A&1[)($6C)FT1*5)NV;HEV*0H``!JARJJHJU
MJJZDJ54O*FHJ)))/<DQ]!F:.FMU&FWT"$MT;*0$(2))3+02`_H8:WR\X4X0Y
MLU:JTW.C6UOZ]3IYW8XEC6+7)58%91S&K18K/U(T/<>E1:.%`3*;H0QQ-ZZ=
MF%YUE&"5SESQY:6JYQO85@`G:>H$SW[_``AF9[Q[C&>,4])D:"NF87N2F9`!
MTU_0(<O2*?`T.FU6C5MF+&NT^NP]8@F1U3.#M8B#8(1L>@=<XB991-HV*!CC
M]1QW$>HZ;-=5OW2J<KJV9J7EE:O\2C,P[[5;:.RVUFTVX2H*=M*$#^ZD2$9/
M[28_NAT_3MU]>GIUUJJ0E4MP^GI&](!)1(;3">REOOV`(_,=Q]/3U'X:SM&I
M\84%%*-@^CPA12(/J7?]8_X;ZP&T!O[0'\,]H0I"5D%0F1%787;;;IUZ#U#J
M&P_VAK(2D)*1])A7AY0GM$Z?2'0!`/7H`AL/3?Y:$(2VG:@22824)*PX1ZQT
M,'MDZ?2'3T]=8^VC73J8R0"K>?JA>TN^^VEQ@I23N/6#L+N([!N/K]NB<9D-
M?/\`5`!"AZ!MN&P_HUDDGK!(`DCJ>L`%*'H&WPTE("1M3T@D-V_]J#L+\@T2
M`.[N8R-)R[]83VR"._:&^VV_7TT*`6)*U`,9!VB0Z14!0#T#;U_O]=*))ZPE
M*0D23H#"ZQ&8UWE7%]2S-CJZXLOT:C,4Z_5N4J]ACU"@`N(Z6:J-EA3.._M.
M&YC%51.'U)JIE,'IKHVJYU5FN+-TH24U3#J5@^:?^W4'R,<N]VFCO]IJ+-<$
MA=)4-*00?,=?EUC@LYL^+WD=PYMTV<]3G\EX:^_K'JF5:E%.)M`\4`J`P:W6
M.CD7#RMV1LB8$UA4*#=P(>XFH(")2_2OC7GW",VH6V7GOP[HA"4J0Z1JM("3
MM5)(,U`R[R(GK'RCY2X$S/`[@XME@U=J6M2D+92H@(*B1,:D2$C(](C75630
M-V+*))*%_;245(51+?\`=4)U,F?Y@.PAJ<_R&BVEY+E.6E"8/WF]1_7$&.43
MS:OM[5ASN%(4@@^'JE/XC2/:KT#8+:_0BZI7Y^TR;DP)MV%9A92>=K*F-VD2
M(A%-':HG/\/IUS*Z^6BC84Y75=,PPD>I1>;]/Z8W:"QWFOJD4]MIUOU2S)*$
M#<I1E,R2-3I/I\8E/XX^&'F]GYRP>3=")@BG.NQ56TY=%2*DP;J>AXVCMA5L
M;Y8"@(@54K0ANFYP#4*99[D>/<0971VJH-RN?[K73_?D4Z>1GY1/^(^USDK+
M7D55Q93;+4H`E3NIEX_;F%:^8CIUX7>'_B_Q#4C+@M'JYAS"T2(8F1+ZP8KH
MP;D>TZIJ95B$4B:Y_$#Z5Q!=[TW][?5.>0>><ZS]!M[[_P"+8@H[66II44_L
MA:QJH@=92!/41>/C7@'">.]E:VW^9>M@W.N":0J0F4(["?0$F0B5M-(4]P[M
MPZ`7?<1``WW$1'U$1'4)Z]!*7Z?G$Y2)45*[]AH!\!VBYV]/AU]?]M]84G>@
MI4>OA&9`&:83LWWW'U^7Z/MWUD@F4C*4+F/`144.T`#Y!MI1,S.$S)U/6%UB
M"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@CQ7/\ES_D?Y;C_,
M?Y;?ZM_O6_3V/]_X;;ZV:3ZD]?J'^7U^7][P\XU*Z7VE_P#+_2?\Z<NG?R\8
MC<NF_P#4<E_^9'\\_P#YKV?U'ZC_`-Q^'O\`S^W?4GM3_'3/_5O3M]'_`(?+
MXQ%%3_S1V_Z0Z]_K^<^_PAQO'S?[HMO_`*6MNX__`,[=OL>H_P`SM^KN^>FU
M>O\`(/\`\Q]7_5?1\_.._9/N?GM2_D4Y_P#3;/N=#]$]/^Z<.E-M].W;_P`W
M?W?4/3NZ[_ITQ#_FG;MGY?5\IZ1(1^GU3G_3]W2/I+^R7]`?X:]T_2)SGY]?
MG+O`.D5:S&8-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H
&@@T01__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
